Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1635jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:35:53 ON 03 MAY 2004

=> FIL MEDLINE BIOSIS EMBASE CA SCISEARCH

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 06:36:01 ON 03 MAY 2004

FILE 'BIOSIS' ENTERED AT 06:36:01 ON 03 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 06:36:01 ON 03 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CA' ENTERED AT 06:36:01 ON 03 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 06:36:01 ON 03 MAY 2004
COPYRIGHT 2004 THOMSON ISI

=> s cd63
L1 2808 CD63

=> s l1 and hiv
L2 51 L1 AND HIV

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 16 DUP REM L2 (35 DUPLICATES REMOVED)

=> s l3 and py=<2000
2 FILES SEARCHED...
L4 9 L3 AND PY=<2000

=> s l4 and antibod?
L5 5 L4 AND ANTIBOD?

=> s l4 and (antibod? or antiser?)
L6 5 L4 AND (ANTIBOD? OR ANTISER?)

=> d l6 1-6 ibib abs

L6 ANSWER 1 OF 5 MEDLINE on STN
ACCESSION NUMBER: 94145751 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8312057
TITLE: Association of host cell surface adhesion receptors and other membrane proteins with **HIV** and SIV.
AUTHOR: Orentas R J; Hildreth J E
CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
CONTRACT NUMBER: 5 R01 AI 31806 (NIAID)
5 T32 CA 09243 (NCI)
SOURCE: AIDS research and human retroviruses, **(1993 Nov)** 9 (11) 1157-65.
Journal code: 8709376. ISSN: 0889-2229.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199403
ENTRY DATE: Entered STN: 19940330
Last Updated on STN: 19970203
Entered Medline: 19940318
AB We have developed a MAb-based capture assay to study the association of host cell membrane proteins with **HIV** and SIV. Class I and II MHC proteins were found to be associated with **HIV** as previously described. In addition to these molecules a number of other host

molecules were found to be acquired by **HIV**, including CD71, **CD63**, CD43, and CD8. We have demonstrated that the major leukocyte adhesion receptors LFA-1 (CD11A/CD18) and CD44 are also associated with **HIV**. The level of surface expression of host membrane proteins did not predict relative expression (capture efficiency) of the virus. The use of virus-susceptible indicator cells showed that the assay involved host membrane protein-mediated capture of infectious **HIV** and SIV particles. Our data indicate that **HIV** and SIV acquire a number of host membrane proteins including adhesion receptors and that this process may be nonrandom. The acquisition of host cell adhesion receptors by **HIV** and SIV could have profound effects on the biology of the viruses, including binding, infectivity, and tropism.

L6 ANSWER 2 OF 5 MEDLINE on STN
ACCESSION NUMBER: 93103619 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1466841
TITLE: Modulation of cell surface molecules during **HIV**-1 infection of H9 cells. An immunoelectron microscopic study.
AUTHOR: Meerloo T; Parmentier H K; Osterhaus A D; Goudsmit J; Schuurman H J
CORPORATE SOURCE: Department of Pathology, University Hospital, Utrecht, The Netherlands.
SOURCE: AIDS (London, England), **(1992 Oct)** 6 (10) 1105-16.
Journal code: 8710219. ISSN: 0269-9370.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199301
ENTRY DATE: Entered STN: 19930212
Last Updated on STN: 19970203
Entered Medline: 19930128

AB OBJECTIVE: To study cell surface molecules and **HIV**-1 proteins on H9 cells 2 days after infection by immunogold electron microscopy, either in single or in double labelling using combinations of host cell-derived molecules and **HIV**-1 proteins. DESIGN AND METHODS: The presence of host cell antigens CD3, CD4 and human leukocyte antigen-DR (HLA-DR) and **HIV**-1 antigens gag p15, p17, p24 and env gp41 was evaluated using immunocytochemistry at the light microscopic level. H9 cells 2 days after infection were processed for conventional transmission electron microscopy and cryo-ultramicrotomy. Leukocyte antigens investigated were CD2, CD3, CD4 (two **antibodies**), CD5, CD8, CD25, CD30, **CD63** antigens and HLA-DR; **HIV**-1-encoded antigens were gag p24, pol reverse transcriptase, and env gp41 and gp120. Double immunogold labelling was performed using reagents with different sized gold particles. For leukocyte markers, the labelling density of the cell membrane was assessed quantitatively on uninfected and infected H9 cells. RESULTS: Infected cells revealed the presence of gag p24, pol, and env gp41 and gp120 antigens on **HIV**-1 virions. Uninfected H9 cells showed a random distribution of cell surface molecules, including CD4 antigen, along the plasma membrane. The **CD63** antigen, a lysosomal membrane glycoprotein, was located mainly in the cytoplasm of uninfected cells. Cells 2 days after infection showed CD4 labelling on sites where virions were budding from or attached to the cell surface and on free virions. Virions also showed labelling by CD3, CD5, CD25, CD30 and **CD63 antibodies** and anti-HLA-DR. Compared with uninfected cells, a significantly lower density was found on infected cells in labelling for CD4, CD5 and anti-HLA-DR. A significantly higher density on cells 2 days after infection was seen in **CD63** labelling. CONCLUSION: During the first phase of infection host cell molecules concentrate on budding structures and newly generated **HIV**-1 virions. This phenomenon might contribute to the

disappearance of these molecules (like the CD4 molecule) from the cell membrane after infection.

L6 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1999:167004 BIOSIS
DOCUMENT NUMBER: PREV199900167004
TITLE: Regulation of class II production after **HIV**-1 infection.
AUTHOR(S): Kraus, T.; Chen, H.; Becker, K.; Rakoff, K. S.; Sperber, K.
CORPORATE SOURCE: Mt. Sinai Sch. Med., New York, NY 10029, USA
SOURCE: FASEB Journal, (March 12, 1999) Vol. 13, No. 4 PART 1, pp. A292. print.
Meeting Info.: Annual Meeting of the Professional Research Scientists for Experimental Biology 99. Washington, D.C., USA. April 17-21, 1999.
CODEN: FAJOEC. ISSN: 0892-6638.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Apr 1999
Last Updated on STN: 19 Apr 1999

L6 ANSWER 4 OF 5 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 133:340273 CA
TITLE: Methods and formulations for targeting infectious agents bearing host cell proteins
INVENTOR(S): Bergeron, Michel G.; Desormeaux, Andre; Tremblay, Michel J.
PATENT ASSIGNEE(S): Infectio Recherche Inc., Can.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000066173	A2	20001109	WO 2000-CA469	20000503	<--
WO 2000066173	A3	20010809			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2270600	AA	20001103	CA 1999-2270600	19990503	<--
EP 1173220	A2	20020123	EP 2000-922374	20000503	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002543162	T2	20021217	JP 2000-615056	20000503	
AU 768685	B2	20031218	AU 2000-42804	20000503	<--
AU 2000042804	A5	20001117			

PRIORITY APPLN. INFO.: CA 1999-2270600 A 19990503
WO 2000-CA469 W 20000503

AB A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition It comprises a ligand capable of binding the host membrane proteins coupled to a lipid-comprising vesicle, which may comprise or not a drug effective in the treatment of the disease. Specific liposomes bearing anti-HLA-DR or

anti-CD4 **antibodies** comprising or not antiviral drugs, namely anti-**HIV** drugs, are disclosed and claimed. A method of formulation as well as a method of using the formulation in the treatment of a disease are also disclosed.

L6 ANSWER 5 OF 5 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 129:92575 CA
TITLE: Method for characterization of abnormal cells using multiple **antibody**- or ligand-coated particles
INVENTOR(S): Fodstad, Oystein; Hoifodt, Hanne Kleppe
PATENT ASSIGNEE(S): Norway
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828622	A1	19980702	WO 1997-NO342	19971216 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
NO 9605531	A	19980622	NO 1996-5531	19961220 <--
AU 9878752	A1	19980717	AU 1998-78752	19971216 <--
AU 728190	B2	20010104		
EP 951645	A1	19991027	EP 1997-949270	19971216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: NO 1996-5531 A 19961220
WO 1997-NO342 W 19971216

AB A method to detect and phenotype target cells in cell suspensions uses particles coated with **antibodies**/ligands directed to antigenic determinants/receptors expressed on the target cells. The method is characterized in that several types of particles are used and each type of particle is instrumentally or visually separable by fluorescence, color and size. Each type of particle is coated with a different **antibody** or ligand. The particles are incubated simultaneously or sequentially with cell suspensions containing the target cells, in connection or not with a per se known enrichment procedure. A kit using the method is also disclosed. A suspension of ascitic cells was incubated with different **antibody**-coated fluorescent particles and paramagnetic immunobeads. The cells were determined to be malignant and epithelial in nature based on the **antibody** particles that bound to the cells.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1635jxs